Abstract: Disclosed is a substrate treating apparatus that performs a heat treatment to a substrate. The apparatus includes the following elements: a heat treating plate; a casing that produces a heat treatment atmosphere by the heat treating plate; a movable top board that is movable between a ceiling surface of the casing and the heat treating plate; and a controller that causes the movable top board to be moved to a raised position when the substrate is loaded/unloaded, and causes the movable top board to be moved to a lowered position when the substrate is placed on the heat treating plate for performing the heat treatment, thereby controlling the lowered position for every substrate.

Abstract: Embodiments provide a coating material including (A) 100 parts by mass of an active-energy-ray-curable resin, (B) 5 to 200 parts by mass of aluminum oxide particles having an average particle diameter of 1 to 100 ?m, (C) 0.1 to 20 parts by mass of aluminum oxide microparticles having an average particle diameter of 1 to 100 nm, and (D) 0.1 to 40 parts by mass of a compound having at least two isocyanate groups per molecule, where the active-energy-ray-curable resin (A) includes (a1) 70 to 99% by mass of a polyfunctional (meth)acrylate and (a2) 30 to 1% by mass of an acrylamide compound having at least one hydroxyl group per molecule, and the sum total of the amount of the polyfunctional (meth)acrylate (a1) and the amount of the acrylamide compound (a2) having at least one hydroxyl group per molecule is 100% by mass.

Abstract: Provided is an aqueous ophthalmic solution comprising diquafosol or a salt thereof at a concentration of 0.1% to 10% (w/v) and a chlorhexidine at a concentration of 0.0001% to 0.1% (w/v).

Abstract: Novel compounds having D3 receptor antagonistic activity are provided. A compound represented by formula (I): wherein ring A is a heterocycle, X1 is each independently CR4aR4b, X2 is each independently CR4cR4d, Y1 and Y2 are each independently a carbon atom or a nitrogen atom, L is —N(R6)—C(?O)— or the like, W is cyclyl or the like, R2 and R3 are each independently substituted or unsubstituted alkyl or the like, R1a, R1b, R4a to R4d, and R6 are each independently hydrogen atoms or the like, p is 1 or 2, q is an integer of 1 to 3, n is an integer of 1 to 4, s is an integer of 0 to 4, or a pharmaceutically acceptable salt thereof.

Abstract: Provided is an aqueous ophthalmic solution comprising diquafosol or a salt thereof at a concentration of 0.1% to 10% (w/v) and a chlorhexidine at a concentration of 0.0001% to 0.1% (w/v).

Abstract: One embodiment is a cosmetic sheet having a transparent adhesive layer (A), a transparent resin film layer (B), a printed layer (C), and a resin film layer (D) in this order from the side adhered to a transparent substrate, where: the transparent resin film layer (B) as a whole has an embossed profile; the printed layer (C) contains a high-brightness pigment; the printed layer (C) as a whole has an embossed profile; and the resin film layer (D) has an embossed profile on the side facing the printed layer (C). Another embodiment is a cosmetic sheet which has a transparent resin layer (E) between the layers of (A) and (B), where this transparent resin layer (E) has an embossed profile on the side facing the transparent resin film layer (B). The adhesive layer (A) may contain prescribed amounts of an acrylic polymer (P) having a glass transition temperature between ?50° C. and ?25° C.

Abstract: Regarding Diquafosol ophthalmic solution comprising a chelating agent at a concentration of 0.0001 to 1% (w/v), formation of insoluble precipitates found in Diquafosol ophthalmic solution during storage of the solution, as well as deterioration of the filtration performance in the course of production (course of filtration sterilization), have been inhibited. Further, in Diquafosol ophthalmic solution comprising a chelating agent, reduction of eye irritation and enhancement of the preservative effectiveness have been confirmed, in comparison to Diquafosol ophthalmic solution comprising no chelating agent. Accordingly, the present invention has been confirmed to provide physicochemical properties that are stable during the courses of production and distribution as well as the course of storage by a patient, and also reduce eye irritation and enhance preservative effectiveness.

Abstract: Regarding Diquafosol ophthalmic solution comprising a chelating agent at a concentration of 0.0001 to 1% (w/v), formation of insoluble precipitates found in Diquafosol ophthalmic solution during storage of the solution, as well as deterioration of the filtration performance in the course of production (course of filtration sterilization), have been inhibited. Further, in Diquafosol ophthalmic solution comprising a chelating agent, reduction of eye irritation and enhancement of the preservative effectiveness have been confirmed, in comparison to Diquafosol ophthalmic solution comprising no chelating agent. Accordingly, the present invention has been confirmed to provide physicochemical properties that are stable during the courses of production and distribution as well as the course of storage by a patient, and also reduce eye irritation and enhance preservative effectiveness.

Abstract: The present invention provides a method for treating or preventing a renal injury-related disease such as diabetic nephropathy comprising administering to a mammal a therapeutically effective amount of 2-({[7-hydroxy-5-(2-phenylethyl)-[1,2,4]triazolo[1,5-a]pyridin-8-yl]carbonyl}amino)acetic acid or a pharmaceutically acceptable salt thereof, and a novel pharmaceutical use of the aforementioned compound such as a pharmaceutical composition for treating or preventing a renal injury-related disease and the like comprising the aforementioned compound or a pharmaceutically acceptable salt thereof.

Abstract: Disclosed is a composition for use for topical administration onto the upper and/or lower eyelid of a subject. The composition includes a polyaphron, and the polyaphron includes: at least one hydrophilic phase; at least one hydrophobic phase; and at least one surfactant selected from ionic surfactants and/or non-ionic surfactants.

Abstract: Provided is an aqueous ophthalmic solution comprising diquafosol or a salt thereof at a concentration of 0.1% to 10% (w/v) and a chlorhexidine at a concentration of 0.0001% to 0.1% (w/v).

Abstract: Regarding Diquafosol ophthalmic solution comprising a chelating agent at a concentration of 0.0001 to 1% (w/v), formation of insoluble precipitates found in Diquafosol ophthalmic solution during storage of the solution, as well as deterioration of the filtration performance in the course of production (course of filtration sterilization), have been inhibited. Further, in Diquafosol ophthalmic solution comprising a chelating agent, reduction of eye irritation and enhancement of the preservative effectiveness have been confirmed, in comparison to Diquafosol ophthalmic solution comprising no chelating agent. Accordingly, the present invention has been confirmed to provide physicochemical properties that are stable during the courses of production and distribution as well as the course of storage by a patient, and also reduce eye irritation and enhance preservative effectiveness.

Abstract: [Task] To provide a method that makes it possible to easily, inexpensively and accurately manufacture a machined part with a simple configuration and an excellent strength. [Means for Solution] In a method for manufacturing a machined part according to the invention, a dislocation is partially introduced (S3), through shot peening, only into a surface layer of a raw material 1 in a region 1a to be machined, graphite is partially deposited (S4), through heating, only in the surface layer of the region 1a to be machined, and then, the surface layer of the region 1a where graphite is deposited is removed, through machining (S5), only by an amount corresponding to a working margin 1c, thereby manufacturing a machined part 1?.

Abstract: Regarding Diquafosol ophthalmic solution comprising a chelating agent at a concentration of 0.0001 to 1% (w/v), formation of insoluble precipitates found in Diquafosol ophthalmic solution during storage of the solution, as well as deterioration of the filtration performance in the course of production (course of filtration sterilization), have been inhibited. Further, in Diquafosol ophthalmic solution comprising a chelating agent, reduction of eye irritation and enhancement of the preservative effectiveness have been confirmed, in comparison to Diquafosol ophthalmic solution comprising no chelating agent. Accordingly, the present invention has been confirmed to provide physicochemical properties that are stable during the courses of production and distribution as well as the course of storage by a patient, and also reduce eye irritation and enhance preservative effectiveness.

Abstract: A method of manufacturing a ferrous metal component includes: performing an element removal treatment on a workpiece formed of a ferrous metal material; and performing a surface hardening treatment on the workpiece through a carburizing treatment after the element removal treatment. In this method, the element removal treatment is performed under a condition of a higher temperature and a lower pressure than in the carburizing treatment.

Abstract: A distorted image (S) is acquired through a photographing operation using a wide-angle lens or an omnidirectional mirror. A cutting reference point (P) for cutting a partial cut region from the distorted image is set. The cut region is set according to the cutting reference point. An eye vector (n) corresponding to the cutting reference point is set with a photographing viewpoint of the distorted image as a base point. The cut region is shifted by a predetermined distance from the cutting reference point. The shifted cut region is transformed through image transformation to transform the distorted image into a planar regular image (T?) according to the eye vector. The shifted cut region (E?) is transformed.

Abstract: A manufacturing method of steel in which an element of the treatment gas is dissolved and diffused includes heating the steel, making a treatment gas contact a surface of the steel such that an element of the treatment gas dissolves and diffuses from the surface of the steel into a surface layer thereof, and reducing a concentration of the treatment gas near a non-treatment surface that is a portion of the surface of the steel.

Abstract: A method of heat treating metal articles includes a heating process of heating a metal workpiece under a predetermined heating condition, a cooling process of cooling the workpiece by spraying mist of cooling water to the workpiece under a predetermined cooling condition after heating the workpiece, and a surface treatment process of adjusting a surface roughness of the workpiece prior to the heating process in line with a thermal distribution in the workpiece heated during the heating process.

Abstract: [Task] To provide a method that makes it possible to easily, inexpensively and accurately manufacture a machined part with a simple configuration and an excellent strength. [Means for Solution] In a method for manufacturing a machined part according to the invention, a dislocation is partially introduced (S3), through shot peening, only into a surface layer of a raw material 1 in a region 1a to be machined, graphite is partially deposited (S4), through heating, only in the surface layer of the region 1a to be machined, and then, the surface layer of the region 1a where graphite is deposited is removed, through machining (S5), only by an amount corresponding to a working margin 1c, thereby manufacturing a machined part 1?.

Abstract: Regarding Diquafosol ophthalmic solution comprising a chelating agent at a concentration of 0.0001 to 1% (w/v), formation of insoluble precipitates found in Diquafosol ophthalmic solution during storage of the solution, as well as deterioration of the filtration performance in the course of production (course of filtration sterilization), have been inhibited. Further, in Diquafosol ophthalmic solution comprising a chelating agent, reduction of eye irritation and enhancement of the preservative effectiveness have been confirmed, in comparison to Diquafosol ophthalmic solution comprising no chelating agent. Accordingly, the present invention has been confirmed to provide physicochemical properties that are stable during the courses of production and distribution as well as the course of storage by a patient, and also reduce eye irritation and enhance preservative effectiveness.